June 18, 2018 09:46 AM EDTUpdated June 19, 11:52 AM
News Briefing

Sev­en biotech IPOs ready to roll; Cell­tri­on's Her­ceptin biosim gets sec­ond re­view at FDA

John Carroll

Editor & Founder

→ Re­nais­sance Cap­i­tal is track­ing 7 new biotech IPOs this week. The line­up in­cludes Ma­gen­ta, Avro­bio and Au­to­lus, all high-pro­file ven­tures that will be …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

A service from the Financial Times